300529: Jafron Biomedical Co.,Ltd. - Summary | Jitta

Jafron Biomedical Co.,Ltd.

CHN:300529

Price
CN¥18.67
Loss Chance
47.7%
5.69JITTA SCORE
238.06%Over Jitta Line
Jitta Ranking
45 / 489
482 / 5,285
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (42)
Recent Business Performance (85)
Financial Strength (89)
Return to Shareholders (59)
Competitive Advantage (63)
Jitta Signs
Debt LevelLow Long Term Debt
Share RepurchaseEvery Year
Interest Coverage RatioVery Good
Revenue and EarningRevenue decline from 2022-2025
Operating MarginInconsistent
Recent Business PerformanceEarning decline 28.84% in the last year
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
5.69
238.06%
4.24
> 1,000%
Health Care Equipment
6.66
2.22%
5.87
35.36%
4.58
6.96%
COMPANY DESCRIPTION
Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification machine; and other products, such as JM hemodialyzer, DNA230, disinfectant, hemodialysis concentrate, resin bandage, online hemodialysis B powder bag/bucket, PGA absorbable suture with needle, syringe and infusion pumps. The company was founded in 1989 and is based in Zhuhai, China.